Abstract
siRNA inhibits protein expression by degrading complementary mRNA sequence and hence, it is widely applicable for the treatment of various diseases where single or multiple gene knock down is necessary. Due to the severity and lethality of pulmonary diseases, siRNA has been focused for improved health in these diseases. Pulmonary accumulation of siRNA can be achieved by different means like intranasal or inhalation administration or intratracheal route which is mainly utilized for in vivo animal studies. However, various pulmonary obstacles and intracellular barriers for siRNA transport challenge this novel therapeutic moiety. Researchers have utilized different viral and non-viral delivery vectors for intracellular delivery of siRNA to knock down target mRNA. The promise of RNA interference, mediated by siRNAs, has revolutionized the prospects for modulating gene expression as a way to achieve therapeutic aims in disease treatment. This review focuses on patents describing the siRNA delivery either in naked form or along with a single/multiple delivery vectors. Many inventors have shown promising results for pulmonary utilization of siRNA and more concentration on delivery system may make this genomic approach available to the clinics soon.
Keywords: Aerosol, dry powder inhaler, genomics, intranasal, lung, nebulizer, pulmonary delivery, siRNA, INTRATRACHEAL ROUTE, RESPIRATORY SYNCYTIAL VIRUS
Recent Patents on Drug Delivery & Formulation
Title: Patents Review in siRNA Delivery for Pulmonary Disorders
Volume: 6 Issue: 1
Author(s): Nirav I. Khatri, Mohan N. Rathi, Atul A. Kolte, Girish G. Kore, Manisha S. Lalan, Sonia Trehan and Ambikanandan R. Misra
Affiliation:
Keywords: Aerosol, dry powder inhaler, genomics, intranasal, lung, nebulizer, pulmonary delivery, siRNA, INTRATRACHEAL ROUTE, RESPIRATORY SYNCYTIAL VIRUS
Abstract: siRNA inhibits protein expression by degrading complementary mRNA sequence and hence, it is widely applicable for the treatment of various diseases where single or multiple gene knock down is necessary. Due to the severity and lethality of pulmonary diseases, siRNA has been focused for improved health in these diseases. Pulmonary accumulation of siRNA can be achieved by different means like intranasal or inhalation administration or intratracheal route which is mainly utilized for in vivo animal studies. However, various pulmonary obstacles and intracellular barriers for siRNA transport challenge this novel therapeutic moiety. Researchers have utilized different viral and non-viral delivery vectors for intracellular delivery of siRNA to knock down target mRNA. The promise of RNA interference, mediated by siRNAs, has revolutionized the prospects for modulating gene expression as a way to achieve therapeutic aims in disease treatment. This review focuses on patents describing the siRNA delivery either in naked form or along with a single/multiple delivery vectors. Many inventors have shown promising results for pulmonary utilization of siRNA and more concentration on delivery system may make this genomic approach available to the clinics soon.
Export Options
About this article
Cite this article as:
I. Khatri Nirav, N. Rathi Mohan, A. Kolte Atul, G. Kore Girish, S. Lalan Manisha, Trehan Sonia and R. Misra Ambikanandan, Patents Review in siRNA Delivery for Pulmonary Disorders, Recent Patents on Drug Delivery & Formulation 2012; 6 (1) . https://dx.doi.org/10.2174/187221112799219116
DOI https://dx.doi.org/10.2174/187221112799219116 |
Print ISSN 1872-2113 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4039 |
Related Articles
-
Development of Amino Acid-Based Radiopharmaceuticals for Tumor Imaging
Mini-Reviews in Medicinal Chemistry Gender Differences in the Antioxidant Response to Oxidative Stress in Experimental Brain Tumors
Current Cancer Drug Targets The Synthesis, Structural Modification and Mode of Anticancer Action of Evodiamine: A Review
Recent Patents on Anti-Cancer Drug Discovery Bypassing Cancer Resistance by Antagonizing “Inhibitor of Apoptosis Proteins” (IAPs)
Current Signal Transduction Therapy Integrins in Drug Targeting-RGD Templates in Toxins
Current Pharmaceutical Design A Novel Lily-of-the-Valley Fragrance Contrast Agent for Magnetic Resonance and Fluorescence Imaging of Prostate Cancer Cells
Current Pharmaceutical Biotechnology New Aspects of Regulatory Signaling Pathways and Novel Therapies in Pancreatic Cancer
Current Molecular Medicine Hybrid Compounds Containing Carvacrol Scaffold: <i>In Vitro</i> Antibacterial and Cytotoxicity Evaluation
Recent Advances in Anti-Infective Drug Discovery Elastin-Like Recombinamers As Smart Drug Delivery Systems
Current Drug Targets Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy
Current Cancer Drug Targets Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery Cannabinoid System as a Potential Target for Drug Development in the Treatment of Cardiovascular Disease
Current Vascular Pharmacology Human Apurinic/Apyrimidinic Endonuclease (APE1): An Emerging Anti-Cancer Biomarker
Recent Patents on Biomarkers Structure Prediction of Neuroendocrine Convertase -2: A Potential Target in Various Cancers
Protein & Peptide Letters The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets
Current Medicinal Chemistry Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging
Mini-Reviews in Medicinal Chemistry The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Current Molecular Medicine ETS Proteins and MMPs: Partners in Invasion and Metastasis
Current Drug Targets Harnessing the Capacity of Cell-Penetrating Peptides for Drug Delivery to the Central Nervous System
Current Pharmaceutical Biotechnology Metabolism of the Endocannabinoids Anandamide and 2-Arachidonoyl Glycerol, A Review, with Emphasis on the Pharmacology of Fatty Acid Amide Hydrolase, A Possible Target for the Treatment of Neurodegenerative Diseases and Pain
Current Medicinal Chemistry - Central Nervous System Agents